Orchestra BioMed Holdings (OBIO) risk factors
Item 1A of every Orchestra BioMed Holdings, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors72 risks40 new14 dropped19 reworded
Orchestra BioMed continues to incur mounting net losses with substantial accumulated deficits. Clinical studies for Virtue SAB, AVIM Therapy, CNT-HF, and SirolimusEFR face lengthy regulatory approval risks. Operations depend heavily on attracting specialized personnel and managing IT systems.
Filed Mar 12, 2026 - FY2024 10-K risk factors46 risks
Company is a clinical-stage medical technology business facing substantial capital requirements for studies like BACKBEAT and Virtue ISR-US. Operations depend heavily on partnerships such as Terumo, Medtronic, and Haemonetics. Product candidates like Virtue SAB face complex drug-device combination regulatory pathways.
Filed Mar 31, 2025